Literature DB >> 30539364

Confidence intervals for the cumulative incidence function via constrained NPMLE.

Paul Blanche1,2,3.   

Abstract

The cumulative incidence function (CIF) displays key information in the competing risks setting, which is common in medical research. In this article, we introduce two new methods to compute non-parametric confidence intervals for the CIF. First, we introduce non-parametric profile-likelihood confidence intervals. The method builds on constrained non-parametric maximum likelihood estimation (NPMLE), for which we derive closed-form formulas. This method can be seen as an extension of that of Thomas and Grunkemeier (J Am Stat Assoc 70:865-871, 1975) to the competing risks setting, when the CIF is of interest instead of the survival function. Second, we build on constrained NPMLE to introduce constrained bootstrap confidence intervals. This extends an interesting approach introduced by Barber and Jennison (Biometrics 52:430-436, 1999) to the competing risks setting. A simulation study illustrates how these methods can perform as compared to benchmarks implemented in popular software. The results suggest that more accurate confidence intervals than usual Wald-type ones can be obtained in the case of small to moderate sample sizes and few observed events. An application to melanoma data is provided for illustration purpose.

Entities:  

Keywords:  Bootstrap; Censoring; Competing risks; Constrained maximum likelihood; Empirical likelihood; Profile likelihood

Mesh:

Year:  2018        PMID: 30539364     DOI: 10.1007/s10985-018-09458-6

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  10 in total

1.  Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data.

Authors:  Jahar B Choudhury
Journal:  Stat Med       Date:  2002-04-30       Impact factor: 2.373

2.  Symmetric tests and confidence intervals for survival probabilities and quantiles of censored survival data.

Authors:  S Barber; C Jennison
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

Review 3.  Competing risks in epidemiology: possibilities and pitfalls.

Authors:  Per Kragh Andersen; Ronald B Geskus; Theo de Witte; Hein Putter
Journal:  Int J Epidemiol       Date:  2012-01-09       Impact factor: 7.196

4.  Comparing the small sample performance of several variance estimators under competing risks.

Authors:  Thomas M Braun; Zheng Yuan
Journal:  Stat Med       Date:  2007-02-28       Impact factor: 2.373

5.  Non-parametric inference for cumulative incidence functions in competing risks studies.

Authors:  D Y Lin
Journal:  Stat Med       Date:  1997-04-30       Impact factor: 2.373

Review 6.  A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions.

Authors:  Aurelien Latouche; Arthur Allignol; Jan Beyersmann; Myriam Labopin; Jason P Fine
Journal:  J Clin Epidemiol       Date:  2013-02-14       Impact factor: 6.437

7.  Pointwise confidence intervals for a survival distribution with small samples or heavy censoring.

Authors:  Michael P Fay; Erica H Brittain; Michael A Proschan
Journal:  Biostatistics       Date:  2013-04-30       Impact factor: 5.899

8.  Competing risk bias was common in a prominent medical journal.

Authors:  Martin Schumacher; Kristin Ohneberg; Jan Beyersmann
Journal:  J Clin Epidemiol       Date:  2016-08-01       Impact factor: 6.437

9.  Survival with malignant melanoma: a regression analysis of prognostic factors.

Authors:  K T Drzewiecki; P K Andersen
Journal:  Cancer       Date:  1982-06-01       Impact factor: 6.860

10.  The use of group sequential designs with common competing risks tests.

Authors:  Brent R Logan; Mei-Jie Zhang
Journal:  Stat Med       Date:  2012-09-04       Impact factor: 2.373

  10 in total
  1 in total

Review 1.  The Wally plot approach to assess the calibration of clinical prediction models.

Authors:  Paul Blanche; Thomas A Gerds; Claus T Ekstrøm
Journal:  Lifetime Data Anal       Date:  2017-12-06       Impact factor: 1.588

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.